Please login to the form below

Not currently logged in
Email:
Password:

ALK inhibitor

This page shows the latest ALK inhibitor news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval for first-line NSCLC

Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval for first-line NSCLC

Lorbrena is also an important follow-up to Pfizer’s older ALK inhibitor Xalkori, which has come under pressure as it faces increasing competition from Roche’s Alecensa (alectinib) and Novartis’ ... Zykadia (ceritinib), with both therapies having

Latest news

  • Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial

    Pfizer’s Lorbrena has come out on top in a head-to-head trial against its older ALK inhibitor Xalkori in previously untreated non-small cell lung cancer (NSCLC) with this ... Follow-up ALK inhibitors are particularly crucial in this treatment setting,

  • Pfizer’s Xalkori follow-up Lorbrena hits the mark in first-line lung cancer Pfizer’s Xalkori follow-up Lorbrena hits the mark in first-line lung cancer

    ALK inhibitor improved progression-free survival in first-line setting. Results from a phase 3 study of Pfizer’s third-generation ALK inhibitor Lorbrena have come back positive as the pharma ... other healthcare providers, as well as engage with global

  • Pfizer’s Talzenna cleared for breast cancer in Europe Pfizer’s Talzenna cleared for breast cancer in Europe

    Fourth to market aims to carve out niche. EU regulators have approved Pfizer’s PARP inhibitor Talzenna to treat patients with BRCA-mutated breast cancer, opening up another front in a ... Talzenna is one of four new targeted therapies it is hoping will

  • Pfizer gets EU nod for Tagrisso rival Vizimpro Pfizer gets EU nod for Tagrisso rival Vizimpro

    Last November, the drugmaker claimed FDA approval for Xalkori follow-up Lorbrena (lorlatinib) in second-line ALK-positive NSCLC and SMO inhibitor Daurismo (glasdegib) for acute myeloid leukaemia, while in October ... it got a green light for PARP

  • Pfizer claims rapid FDA nod for Lorbrena Pfizer claims rapid FDA nod for Lorbrena

    The FDA has granted approval to Pfizer's next generation ALK inhibitor lung cancer treatment Lorbrena, which will help it defend its presence in the market. ... Follow-up ALK inhibitors are important in this treatment pathway, as many experience tumour

More from news
Approximately 3 fully matching, plus 32 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Iguazu

Iguazu Ltd is a digital healthcare agency, delivering tactical and innovative solutions. WHAT WE DO We are Closed Loop Marketing...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...